IRIS
PUGLISI, Fabio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.280
EU - Europa 4.952
AS - Asia 3.730
SA - Sud America 566
AF - Africa 70
Continente sconosciuto - Info sul continente non disponibili 18
OC - Oceania 8
Totale 26.624
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.160
SG - Singapore 1.982
UA - Ucraina 1.244
CN - Cina 949
IT - Italia 776
DE - Germania 755
RU - Federazione Russa 544
BR - Brasile 522
FI - Finlandia 411
SE - Svezia 314
IE - Irlanda 308
GB - Regno Unito 158
VN - Vietnam 149
TR - Turchia 145
IN - India 144
KR - Corea 143
CA - Canada 92
FR - Francia 78
AT - Austria 65
HK - Hong Kong 65
BE - Belgio 52
NL - Olanda 52
CZ - Repubblica Ceca 41
CH - Svizzera 31
PL - Polonia 31
TG - Togo 30
IR - Iran 26
RO - Romania 25
BD - Bangladesh 18
EU - Europa 16
AR - Argentina 14
ES - Italia 12
JP - Giappone 12
MX - Messico 12
IQ - Iraq 11
ZA - Sudafrica 11
EC - Ecuador 10
LT - Lituania 10
PK - Pakistan 9
CO - Colombia 8
EG - Egitto 8
MA - Marocco 8
LV - Lettonia 7
UZ - Uzbekistan 7
AM - Armenia 6
AU - Australia 6
AZ - Azerbaigian 6
BG - Bulgaria 6
IL - Israele 6
PE - Perù 6
TN - Tunisia 6
EE - Estonia 5
ID - Indonesia 5
JM - Giamaica 5
KG - Kirghizistan 5
LA - Repubblica Popolare Democratica del Laos 5
AL - Albania 4
BY - Bielorussia 4
NP - Nepal 4
SA - Arabia Saudita 4
AE - Emirati Arabi Uniti 3
DK - Danimarca 3
JO - Giordania 3
KZ - Kazakistan 3
LB - Libano 3
PA - Panama 3
RS - Serbia 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
CL - Cile 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GR - Grecia 2
LK - Sri Lanka 2
MD - Moldavia 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PH - Filippine 2
PT - Portogallo 2
TH - Thailandia 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
CI - Costa d'Avorio 1
CM - Camerun 1
CR - Costa Rica 1
GE - Georgia 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IS - Islanda 1
KE - Kenya 1
KH - Cambogia 1
MN - Mongolia 1
NG - Nigeria 1
NO - Norvegia 1
PS - Palestinian Territory 1
Totale 26.619
Salva come PNG Salva come JPEG
Città #
Fairfield 2.560
Woodbridge 1.760
Ashburn 1.319
Houston 1.247
Chandler 1.120
Singapore 1.076
Ann Arbor 1.010
Seattle 1.001
Wilmington 903
Cambridge 854
Jacksonville 810
Dearborn 547
Boardman 452
Beijing 426
Dublin 302
Princeton 298
Udine 188
Dong Ket 145
San Diego 141
Seoul 134
Izmir 125
New York 116
Des Moines 84
Ogden 84
Los Angeles 69
Hong Kong 65
Nuremberg 64
Munich 56
Hefei 55
Ottawa 52
Norwalk 50
Brussels 48
Nanjing 45
Guangzhou 40
Kunming 40
Helsinki 39
São Paulo 39
Codroipo 36
Washington 36
Trieste 32
Frankfurt am Main 31
Lomé 30
Milan 30
Santa Clara 30
Brno 29
Redmond 29
Dallas 27
Phoenix 27
Düsseldorf 26
Falls Church 26
Martignacco 26
Zurich 26
Vienna 25
Jinan 24
Venice 24
Warsaw 23
London 22
Hyderabad 21
Turku 21
Lappeenranta 20
Lauterbourg 20
Toronto 20
Leawood 18
Timisoara 18
Genoa 17
Nanchang 17
San Francisco 17
Belluno 16
Grafing 16
Hangzhou 16
Naples 16
San Mateo 16
Ardabil 15
Augusta 15
Shanghai 15
Monmouth Junction 14
Wuhan 14
Portsmouth 13
Shenzhen 13
Brooklyn 12
Newark 12
Rome 12
Amsterdam 11
Arezzo 11
Charlotte 11
Mcallen 11
Simi Valley 11
Brasília 10
Jiaxing 10
Treviso 10
Belo Horizonte 9
Hebei 9
Nürnberg 9
Stockholm 9
Tokyo 9
Council Bluffs 8
Fremont 8
Fuzhou 8
Mexico City 8
Montreal 8
Totale 18.497
Salva come PNG Salva come JPEG
Nome #
Hepatitis B and cancer: A practical guide for the oncologist 198
In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis 184
BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress 172
Role of pre-surgical breast MRI in the management of invasive breast carcinoma 160
Adjuvant endocrine therapy in postmenopausal breast cancer patients: does hormone receptor status influence decision-making? 158
Characterizing metastatic HER2-positive gastric cancer at the CDH1 haplotype 157
Acetylation on critical lysine residues of Apurinic/apyrimidinic endonuclease 1 (APE1) in triple negative breast cancers 156
MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme 150
Role of mammography, ultrasound and large-core biopsy in the diagnostic evaluation of papillary breast lesions 149
Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer 149
Bevacizumab in older patients with advanced colorectal or breast cancer 146
Molecular diagnosis of neoplasms 145
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients 145
First steps in the definition of a prognostic score based on MGMT methylation status in patients with glioblastoma 144
Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibitors on TXNIP expression in breast cancer cells 143
Expression of periostin in human breast cancer 142
Bone scanning in lung cancer [2] (multiple letters) 142
D-dimer and venous thromboembolism 141
B-cell lymphoma presenting as acute pancreatitis 140
Luminal-like HER2-negative stage IA breast cancer: A multicenter retrospective study on long-term outcome with propensity score analysis 140
Bone scanning in lung cancer: pretest probability is of value 139
Gene expression profiling in breast cancer: a clinical perspective. 138
Primary therapy in breast cancer: what have we learned from landmark trials? 137
The SLICE study: The prognostic role of visceral fat in metastatic colorectal cancer 137
Pattern of metastasis and outcome in patients with breast cancer 137
Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy 134
Taxane-induced nail changes: incidence, clinical presentation and outcome 132
BRCA2 GERMLINE MUTATIONS IN PRIMARY CANCER OF THE FALLOPIAN TUBE 132
Trastuzumab and breast cancer. Are we just beyond the prologue of a fascinating story? 130
What does similarity mean in clinical trials? 129
Galectin-3 expression in non-small cell lung carcinoma 129
Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme 129
Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. 128
Predictors of axillary lymph node metastases in patients with T1 breast carcinoma 128
Treatment of metastatic breast cancer in a real-world scenario: Is progression-free survival with first line predictive of benefit from second and later lines? 127
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer 127
Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial. 126
Prognostic evaluation in palliative care: final results from a prospective cohort study 126
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies 125
Angiogenesis and tumor growth 124
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 124
TSH controls ref-1 nuclear translocation in thyroid cells 122
Measures of outcome in metastatic breast cancer: insights from a real-world scenario. 122
Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy 122
A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study 122
Patterns of care and clinical outcomes of first-line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients relapsing after (Neo)adjuvant trastuzumab: An Italian multicenter retrospective cohort study 122
Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients 121
Sonographic criteria for differentiation of benign and malignant solid breast lesions: size is of value 120
Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence 120
Androgen receptor in estrogen receptor positive breast cancer: Beyond expression 120
Hormone therapy in elderly breast cancer patients with comorbidities 119
Vaccination for seasonal influenza in patients with cancer: Recommendations of the Italian Society of Medical Oncology (AIOM) 119
Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example 119
p53 protein expression and p53 mutation in thymic epithelial tumors 118
A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer 118
Expert pathology consultation through the Internet: melanoma versus benign melanocytic tumours 116
Expression and localization of the homeodomain-containing protein HEX in human thyroid tumors 116
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 115
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 114
Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly 114
Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients 113
Capecitabine-induced cardiotoxicity: More evidence or clinical approaches to protect the patients' heart? 113
Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy 113
Telepathology using Internet Multimedia Electronic Mail: Remote Consultation on Gastrointestinal Pathology 112
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial 112
Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole 112
Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker 112
From the podium to the patient: Bringing the 2008 ASCO meeting to the clinic 111
Hot topics and landmark studies from the 43rd annual meeting of the American Society of Clinical Oncology 111
Large core biopsy for diagnostic and prognostic evaluation of invasive breast carcinomas 111
Looking for predictive markers in breast cancer 111
LOCALLY ADVANCED BREAST CANCER: COMPARISON OF MAMMOGRAPHY, SONOGRAPHY AND MR IMAGING IN EVALUATION OF RESIDUAL DISEASE IN WOMEN RECEIVING NEOADJUVANT CHEMOTHERAPY 111
Thymidine phosphorylase expression in metastatic kidney cancer as a potential predictor of outcome in patients treated with sunitinib 110
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): A combined analysis of two phase 3 randomised trials 110
Follow-up of patients with early breast cancer: Is it time to rewrite the story? 110
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results 110
Adjuvant ovarian function suppression and cognitive function in women with breast cancer 110
APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC 109
Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer 109
Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM) 109
Immunocytochemical expression of tissue specific transcription factor-1 in lung carcinoma 108
MR mammography using diffusion-weighted imaging in evaluating breast cancer: a correlation with proliferation index 108
Do platinum salts fit all triple negative breast cancers? 108
Tailoring adjuvant endocrine therapy for premenopausal breast cancer 107
Markers of the uPA system and common prognostic factors in breast cancer 107
Dramatic tumour response to pemetrexed single-agent in an elderly patient with malignant peritoneal mesothelioma: a case report 106
Effect of age on hemoglobin levels and quality of life following treatment with epoetin alfa in cancer patients 106
PROTEOMIC EVALUATION OF CORE BIOPSY SPECIMENS FROM BREAST LESIONS 106
Determinants of Last-line Treatment in Metastatic Breast Cancer 106
Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study 106
Balance between cell division and cell death as predictor of survival in patients with non-small-cell lung cancer 106
The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA) 106
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer 105
Current challenges in HER2-positive breast cancer 105
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 105
First-line chemotherapy with or without biologic agents for metastatic breast cancer 104
Treatment of HER2-positive breast cancer: current status and future perspectives 104
Cognitive functions and elderly cancer patients receiving anticancer treatment: a prospective study 104
Histone deacetylase inhibitors induce thymidine phosphorylase expression in cultured breast cancer cell lines. 104
Information to cancer patients: a questionnaire survey in three different geographical areas in Italy. 104
Totale 12.392
Salva come PNG Salva come JPEG
Categoria #
all - tutte 115.499
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 115.499
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020375 0 0 0 0 0 0 0 0 0 0 0 375
2020/20214.006 112 499 199 572 229 389 225 435 416 168 419 343
2021/20222.555 214 216 83 162 69 142 148 116 40 440 551 374
2022/20232.662 332 191 71 309 270 726 29 205 338 37 90 64
2023/20241.387 123 91 73 51 194 277 41 74 134 109 59 161
2024/20255.646 190 466 304 254 380 418 470 434 768 707 1.195 60
Totale 27.809